CROSS COUNTRY HEALTHCARE INC (CCRN)
Health Care · Healthcare staffing and workforce solutions · NASDAQ
A healthcare staffing company providing temporary and permanent talent solutions, including travel nurses and allied health professionals, to acute-care facilities and health systems.
What CROSS COUNTRY HEALTHCARE INC does
Cross Country Healthcare provides staffing and workforce management solutions to healthcare systems and acute-care facilities. The company supplies temporary clinical and non-clinical staff, permanent placements, and other workforce solutions to hospitals and healthcare networks. The majority of its customers are healthcare systems with significant presence in acute-care facilities, and the company recognizes revenue based on employee, subcontracted employee, and independent contractor time worked.
Themes: Healthcare staffing, Temporary staffing / labor solutions, Permanent recruitment / placement, Acute-care provider staffing
Fundamentals
- Price$13.25 as of 2026-07-28 close
- Market cap$428M as of 2026-07-28
- 1-year return-4.1% 2025-07-28 close $13.81 → 2026-07-28 close $13.25
- P/En/a negative earnings
- Net margin-9.8% as of 2026-08-26
- Gross margin+20.2% as of 2026-08-26
- ROE-27.1% as of 2026-08-26
- Debt / equity0.00 as of 2026-08-26
- Revenue growth (YoY)-20.4% as of 2026-08-26
- Revenue CAGR (3y)-27.8% SEC XBRL
- Beta0.41 as of 2026-08-26
- Last reported earnings2026-05-07 SEC EDGAR Form 8-K (Item 2.02)
How CCRN compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-26
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-26
- gross marginbottom 10% 384 covered Health Care peers, as of 2026-08-26
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-26
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Analyst consensus
- Consensus ratingHold (3.00 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$12.44 range $10.00 – $13.25; median $13.25
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CCRN
- Consensus EPS estimate$0.01667 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Healthcare customer concentration and credit risk—majority of customers are healthcare systems, with receivables requiring 30-60 day payment terms and exposure to healthcare market downturns","Revenue decline and unprofitability—negative revenue growth (-20.37% YoY) and negative net margin (-9.84%) indicate operational challenges and margin pressure in the staffing market","Restructuring and operational transformation—ongoing restructuring activities including headcount reductions and facility consolidations indicate adjustment to changing market conditions"]
What changed in the latest 10-Q
AI-assisted comparison of CCRN's 10-Q filed 2026-05-08 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references 2025 Form 10-K (year ended December 31, 2025) instead of 2024 Form 10-K
- New 'Recent Events' section describing May 6, 2026 merger agreement with KL Criss Cross Intermediate, LLC
- Description of caregiver services to PACE programs as 'home based PACE services' (more specific terminology)
- Q1 2026 revenue of $241.1 million with 17.8% year-over-year decline
- Q1 2026 net loss of $4.3 million attributable to common stockholders
- Q1 2026 cash and cash equivalents of $105.6 million
- Q1 2026 share repurchase of 657,653 shares
- Q1 2026 operating cash flow of $4.8 million
- Q1 2026 ABL borrowing base availability of $109.3 million ($91.0 million net of letters of credit)
- Nurse and Allied Staffing represented 84% of total revenue in Q1 2026
- Physician Staffing represented 16% of total revenue in Q1 2026
- Cross Country Community Care growth of 15.8% year-over-year in Q1 2026
- Removed:
- Reference to 2024 Form 10-K/A (as amended by Amendment No. 1)
- Previous merger discussion with Aya Holdings II Inc. and Spark Merger Sub One Inc.
- References to FTC Second Request, HSR Act review, and December 3, 2025 end date for Aya Merger
- Q3 2025 revenue of $250.1 million with 20.6% year-over-year decline
- Q3 2025 net loss of $4.8 million (compared to Q3 2024 net income of $2.6 million)
- Q3 2025 cash and cash equivalents of $99.1 million
- Q3 2025 operating cash flow of $20.1 million
- Q3 2025 ABL borrowing base availability of $121.4 million ($103.0 million net of letters of credit)
- Nurse and Allied Staffing represented 81% of total revenue in Q3 2025
- Physician Staffing represented 19% of total revenue in Q3 2025
- Homecare Staffing growth of 29.1% year-over-year in Q3 2025
- Reworded:
- Workforce solutions description changed from 'in-home care services' to 'caregiver services to PACE programs (home based PACE services)'
- Single- and multi-specialty physician practices changed to 'single and multi-specialty physician practices' (hyphenation style)
- SaaS description changed from 'SaaS-based' to 'SaaS-based' (no material change, formatting consistency)
- Notes:
- Older filing covers Q3 2025 (September 30, 2025) period; newer filing covers Q1 2026 (March 31, 2026) period—different fiscal quarters being reported
- The merger-related sections describe entirely different transactions (Aya Merger in older filing vs. KL Criss Cross Merger in newer filing)
- Financial metrics and operating results are not directly comparable due to different reporting periods and changing business conditions
Risk Factors
- Added:
- Added disclosure: 'Accounts receivable potentially subject the Company to concentrations of credit risk.' in newer filing (2026-05-08)
- Added new accounting pronouncement: ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, issued December 8, 2025, effective for interim periods after December 15, 2027 (newer filing 2026-05-08)
- Added restructuring table entry showing footnote (a) reference regarding $0.1 million of ongoing lease costs and other direct charges for three months ended March 31, 2026 (newer filing 2026-05-08)
- Removed:
- Removed 'Recently Adopted Accounting Pronouncements' section and ASU No. 2023-07 disclosure about Segment Reporting adopted for fiscal year 2024 and Q1 2025 (older filing 2025-11-12)
- Removed multi-quarter reconciliation table for allowance for credit losses showing balances at March 31, June 30, and September 30 for 2025 and 2024 (older filing 2025-11-12)
- Removed sales allowance balance amounts of $0.4 million (Sept 30, 2025) and $0.5 million (Dec 31, 2024) - replaced with single amounts for March 31, 2026 and December 31, 2025 (newer filing 2026-05-08)
- Removed restructuring table showing quarterly progression through Q1, Q2, and Q3 2025 (older filing 2025-11-12)
- Reworded:
- Changed unbilled accounts receivable amounts from '$51.2 million and $60.4 million at September 30, 2025 and December 31, 2024' to '$54.5 million and $48.3 million at March 31, 2026 and December 31, 2025' (newer filing 2026-05-08)
- Changed allowance for credit losses reconciliation table from nine-row format covering Q1-Q3 2025 to three-row format covering only Q1 2026 (newer filing 2026-05-08)
- Changed reference period for customer concentration disclosure from 'three and nine months ended September 30, 2025 and 2024' to 'three months ended March 31, 2026 and 2025' (newer filing 2026-05-08)
- Changed sales allowance balance disclosure from 'as of September 30, 2025 and December 31, 2024' to 'as of both March 31, 2026 and December 31, 2025' (newer filing 2026-05-08)
- Changed restructuring table header year labels from '2025' and '2024' to '2026' (newer filing 2026-05-08)
- Changed expectation language for ASU 2025-06 impact from 'expects this ASU to have an immaterial impact' to 'is currently in the process of evaluating the potential impact' (newer filing 2026-05-08)
- Notes:
- Newer filing covers quarter ended March 31, 2026 while older filing covers quarter ended September 30, 2025; period-specific data differences reflect timing rather than policy changes
- ASU 2025-11 was newly issued December 8, 2025, between the two filing dates, explaining its addition in the newer filing
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 1 sell ($60146) — 1 selling insider
Most recent open-market transaction: 2026-03-11. As of 2026-08-26.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CCRN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CCRN as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 4,411,858
- Reported value $41,471,468
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CCRN had 824,403 shares of reported short interest as of the 2026-07-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CCRN had 2.55% of its shares outstanding sold short as of the 2026-07-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.74 days to cover at the same settlement.
- Reported short interest (shares) 824,403
- Short interest (% of shares outstanding) 2.55%
- Prior settlement (shares) 871,295
- Reported change -5.38%
- Days to cover (reported) 1.74
Reported to FINRA as of the 2026-07-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Aya Healthcare
- AMN Healthcare
- Maxim Healthcare Services
- Staffing 360 Solutions
- On Assignment (now Apex Group)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CCRN vs…
Frequently asked questions
What does CROSS COUNTRY HEALTHCARE INC (CCRN) do?
Cross Country Healthcare provides staffing and workforce management solutions to healthcare systems and acute-care facilities. The company supplies temporary clinical and non-clinical staff, permanent placements, and other workforce solutions to hospitals and healthcare networks. The majority of its customers are healthcare systems with significant presence in acute-care facilities, and the company recognizes revenue based on employee, subcontracted employee, and independent contractor time…
What sector is CROSS COUNTRY HEALTHCARE INC (CCRN) in?
CROSS COUNTRY HEALTHCARE INC (CCRN) is classified in the Health Care sector. Its industry is Healthcare staffing and workforce solutions. It trades on NASDAQ.
Who are CROSS COUNTRY HEALTHCARE INC's (CCRN) competitors?
Notable peers of CROSS COUNTRY HEALTHCARE INC (CCRN) include Aya Healthcare, AMN Healthcare, Maxim Healthcare Services, Staffing 360 Solutions and On Assignment (now Apex Group). This peer set is informational only — not financial advice.
Where does stocks-llm's data on CCRN come from?
Fundamentals and prices come from market data, as of 2026-08-26; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-28.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.